Fourteen entries will be vying for the prestigious 2006 UK Prix Galien Award it was announced today. The entries are:
• Alvesco - Altana Pharma (Respiratory)
• Alimta - Eli Lilly and Company (Oncology)
• Myozyme - Genzyme Speciality Therapeutics (Metabolic disorders)
• Rotarix - GlaxoSmithKline (Gastroenterology)
• Erbitux - Merck Pharmaceuticals (Oncology)
• Moviprep - Norgine (Gastroenterology)
• Movicol Paediatric (Gastroenterology)
• Xolair - Novartis (Respiratory)
• Aromasin - Pfizer (Oncology)
• Lyrica - Pfizer (Neurology)
• Avastin - Roche (Oncology)
• Tarceva - Roche (Oncology)
• Zevalin - Schering Healthcare (Oncology)
• Protelos - Servier Laboratories (Endocrine system)
The award recognises outstanding achievement in pharmaceutical research and development, and is presented to the most innovative treatment to have been recently developed in the UK.
The independent judging committee members currently range from experts within the National Institute of Clinical Excellence (NICE) and the Scottish Medicines Consortium (SMC) through to leading medical consultants, academics and a media doctor.
When deciding upon the winners they have been asked to identify the medicines that have made the most significant contribution to patient care in the UK. They also judge against broader themes such as efficacy, safety, benefits and innovation.
The overall winning entry will receive the gold Prix Galien medal. Previous winners of this highly prestigious honour are Herceptin, Prevenar and Viagra.
The Awards ceremony will be held at the Houses of Parliament on 26 September 2006.
For further details, or to arrange an interview with Prix Galien judges Professor Sir Michael Rawlins (NICE) or Professor Parveen Kumar (BMA) please contact Sarah Beyrath at Right Angle Learning: Sarah.Beyrath@ralearning.com. Ph: 020 8834 1039 or 07958672239